Cytokinetics (CYTK) Total Liabilities (2010 - 2026)

Cytokinetics (CYTK) has reported Total Liabilities for 17 consecutive years, with $2.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities rose 37.22% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $2.1 billion (up 37.22% YoY), while the FY2025 annual figure was $2.1 billion, up 35.6% from the prior year.
• Total Liabilities advanced to $2.1 billion in Q1 2026 per CYTK's latest filing, from $2.1 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $2.1 billion in Q1 2026 and bottomed at $660.3 million in Q2 2022.
• Historically, Total Liabilities has averaged $1.4 billion across 5 years, with a median of $1.2 billion in 2023.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 88.75% — and 2024, when it gained 7.63%.
• Cytokinetics' Total Liabilities stood at $1.1 billion in 2022, then climbed by 7.84% to $1.2 billion in 2023, then climbed by 26.96% to $1.5 billion in 2024, then surged by 35.6% to $2.1 billion in 2025, then climbed by 0.76% to $2.1 billion in 2026.
• Business Quant data shows CYTK's Total Liabilities at $2.1 billion in Q1 2026, $2.1 billion in Q4 2025, and $2.0 billion in Q3 2025.